A case with familial hypercholesterolemia complicated with severe systemic atherosclerosis intensively treated for more than 30 years.
Atherosclerosis
Familial hypercholesterolemia
Low-density lipoprotein cholesterol
Transcatheter aortic valve implantation
Journal
Journal of cardiology cases
ISSN: 1878-5409
Titre abrégé: J Cardiol Cases
Pays: Japan
ID NLM: 101549579
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
25
02
2020
revised:
14
05
2020
accepted:
20
06
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
We present a case of a Japanese patient with familial hypercholesterolemia (FH) caused by a low-density lipoprotein (LDL) receptor gene mutation. A 47-year-old female was referred to our hospital due to her systemic xanthomatosis associated with elevated LDL-cholesterolemia (292 mg/dl). She was diagnosed with heterozygous FH, and started to be treated with simvastatin 10 mg. During her clinical course, she underwent percutaneous coronary intervention (PCI) (at 69 years), coronary artery bypass grafting (CABG) twice (at 62 years, and 75 years), femoral popliteal bypass surgery (at 67 years), together with intensification of lipid-lowering therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. She was admitted to our hospital due to dyspnea on effort, caused by severe aortic valve stenosis as well as sick sinus syndrome at the age of 78 years. transcatheter aortic valve implantation (TAVI) using balloon expandable valve was successfully performed after DDD pacemaker implantation. She was discharged from our hospital without any symptoms. During more than 30 years of treatment period in our institute, we have introduced the latest therapeutic strategies, and treated her intensively. We are proud that we can save life even in this severe case through multiple strategies developed over the decades; however, this case clearly suggests that lipid-lowering therapies should be started much earlier in patients with FH. <
Identifiants
pubmed: 33133313
doi: 10.1016/j.jccase.2020.06.012
pii: S1878-5409(20)30073-6
pmc: PMC7588487
doi:
Types de publication
Case Reports
Langues
eng
Pagination
216-220Informations de copyright
© 2020 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Références
Am J Cardiol. 2017 Dec 1;120(11):1955-1960
pubmed: 28947310
J Clin Lipidol. 2018 Nov - Dec;12(6):1436-1444
pubmed: 30241732
J Clin Lipidol. 2019 Jan - Feb;13(1):138-147
pubmed: 30591415
J Atheroscler Thromb. 2017 Mar 1;24(3):189-207
pubmed: 28179607
Eur Heart J. 2017 May 21;38(20):1573-1579
pubmed: 28159968
Am J Cardiol. 2015 Mar 15;115(6):724-9
pubmed: 25618577
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
J Atheroscler Thromb. 2018 Aug 1;25(8):751-770
pubmed: 29877295
J Atheroscler Thromb. 2010 Jul 30;17(7):667-74
pubmed: 20534948
J Am Coll Cardiol. 2008 Oct 21;52(17):1421-9
pubmed: 18940534